Bris­tol My­er­s' Op­di­vo notch­es a dou­ble win against chemo in esophageal can­cer, po­ten­tial­ly set­ting up 1st-line nod

Bris­tol My­ers Squibb is one of a group of drug­mak­ers prep­ping for a tense FDA ad­comm lat­er this month to re­view a host of ac­cel­er­at­ed ap­provals. Look­ing to start the month on the right note, the drug­mak­er rolled out new da­ta for its PD-(L)1 check­point in­hibitor Op­di­vo show­ing more promise in esophageal can­cer.

Op­di­vo in com­bi­na­tion with chemother­a­py and a com­bi­na­tion of Op­di­vo and Yer­voy beat out chemo alone in ex­tend­ing the lives of first-line esophageal squa­mous cell car­ci­no­ma pa­tients whose tu­mors are metasta­t­ic or can’t be sur­gi­cal­ly re­moved, ac­cord­ing to in­ter­im re­sults re­leased Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER